Protagonist Therapeutics (PTGX) Cash from Operations (2017 - 2025)
Historic Cash from Operations for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$1.9 million.
- Protagonist Therapeutics' Cash from Operations rose 9304.81% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.5 million, marking a year-over-year decrease of 7157.15%. This contributed to the annual value of $184.2 million for FY2024, which is 36219.03% up from last year.
- Protagonist Therapeutics' Cash from Operations amounted to -$1.9 million in Q3 2025, which was up 9304.81% from -$28.8 million recorded in Q2 2025.
- Protagonist Therapeutics' Cash from Operations' 5-year high stood at $268.6 million during Q2 2024, with a 5-year trough of -$37.7 million in Q1 2022.
- In the last 5 years, Protagonist Therapeutics' Cash from Operations had a median value of -$26.9 million in 2021 and averaged -$391578.9.
- Examining YoY changes over the last 5 years, Protagonist Therapeutics' Cash from Operations showed a top increase of 112378.99% in 2024 and a maximum decrease of 27204.01% in 2024.
- Protagonist Therapeutics' Cash from Operations (Quarter) stood at -$26.9 million in 2021, then decreased by 17.43% to -$31.6 million in 2022, then skyrocketed by 153.61% to $17.0 million in 2023, then tumbled by 272.04% to -$29.2 million in 2024, then soared by 93.36% to -$1.9 million in 2025.
- Its last three reported values are -$1.9 million in Q3 2025, -$28.8 million for Q2 2025, and $125.4 million during Q1 2025.